Form 8-K · Current Report · Filed 2026-05-07
BD Announces Second Fiscal Quarter Financial Results
On May 7, 2026, Becton, Dickinson and Company (BD) announced its financial results for the second fiscal quarter ending March 31, 2026.
- Filer
- Becton, Dickinson and Company BDX · NYSE
- Filed
- Accession
- 0001628280-26-031638
- CIK
- 0000010795
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The company issued a press release that included certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (non-GAAP measures). Details regarding these non-GAAP measures and adjustments can be found in the schedules included in the press release.
Items reported
Reported Item
Market reaction
Close before filing
$144.76
Next session
+3.2%
Since filing
+14.4%
Latest close
$165.62
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from BDX reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, BDX insiders reported 10 Form 4 transactions — net selling of $535K.
About Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.
Never miss another BDX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.